136 related articles for article (PubMed ID: 1283750)
21. Medical treatment for inoperable malignant bowel obstruction: a qualitative systematic review.
Mercadante S; Casuccio A; Mangione S
J Pain Symptom Manage; 2007 Feb; 33(2):217-23. PubMed ID: 17280927
[TBL] [Abstract][Full Text] [Related]
22. Octreotide may prevent definitive intestinal obstruction.
Mercadante S; Kargar J; Nicolosi G
J Pain Symptom Manage; 1997 Jun; 13(6):352-5. PubMed ID: 9204656
[TBL] [Abstract][Full Text] [Related]
23. SALTO: a randomized, multicenter study assessing octreotide LAR in inoperable bowel obstruction.
Laval G; Rousselot H; Toussaint-Martel S; Mayer F; Terrebonne E; François E; Brixi H; Nguyen T; Bourdeix I; Bisot-Locard S; Zelek L;
Bull Cancer; 2012 Feb; 99(2):E1-9. PubMed ID: 22265994
[TBL] [Abstract][Full Text] [Related]
24. How to use octreotide for malignant bowel obstruction.
Ripamonti C; Mercadante S
J Support Oncol; 2004; 2(4):357-64. PubMed ID: 15357519
[No Abstract] [Full Text] [Related]
25. Malignant irreversible intestinal obstruction: the powerful association of octreotide to corticosteroids, antiemetics, and analgesics.
Weber C; Zulian GB
Am J Hosp Palliat Care; 2009; 26(2):84-8. PubMed ID: 19088264
[TBL] [Abstract][Full Text] [Related]
26. The challenge of treating malignant bowel obstruction.
J Support Oncol; 2006 Feb; 4(2):83-4. PubMed ID: 16499129
[No Abstract] [Full Text] [Related]
27. Clinician-reported changes in octreotide prescribing for malignant bowel obstruction as a result of an adequately powered phase III study: A transnational, online survey.
Campbell R; McCaffrey N; Brown L; Agar MR; Clark K; Currow DC
Palliat Med; 2018 Sep; 32(8):1363-1368. PubMed ID: 29856291
[TBL] [Abstract][Full Text] [Related]
28. Scopolamine butylbromide plus octreotide in unresponsive bowel obstruction.
Mercadante S
J Pain Symptom Manage; 1998 Nov; 16(5):278-80. PubMed ID: 9846021
[No Abstract] [Full Text] [Related]
29. Hepatic portal venous gas: a rare complication of malignant bowel obstruction during the administration of octreotide.
Maeda I; Tsuneto S; Yasui Y; Ueda Y; Kimura T
J Pain Symptom Manage; 2014 Feb; 47(2):e2-5. PubMed ID: 24388125
[No Abstract] [Full Text] [Related]
30. Radiological imaging change in a malignant bowel obstruction patient treated with octreotide.
Shinjo T; Kagami R
Support Care Cancer; 2009 Jun; 17(6):753-5. PubMed ID: 19277723
[TBL] [Abstract][Full Text] [Related]
31. Can malignant bowel obstruction in advanced cancer patients be treated at home?
Porzio G; Aielli F; Verna L; Galletti B; Shoja E Razavi G; Ficorella C
Support Care Cancer; 2011 Mar; 19(3):431-3. PubMed ID: 20872024
[TBL] [Abstract][Full Text] [Related]
32. Why not octreotide?
Mercadante S
Support Care Cancer; 1994 May; 2(3):205-6. PubMed ID: 7913384
[No Abstract] [Full Text] [Related]
33. Pathophysiology and palliation of inoperable bowel obstruction in patients with ovarian cancer.
Jatoi A; Podratz KC; Gill P; Hartmann LC
J Support Oncol; 2004; 2(4):323-34; discussion 334-7. PubMed ID: 15357517
[TBL] [Abstract][Full Text] [Related]
34. Medical Therapy of Malignant Bowel Obstruction With Octreotide, Dexamethasone, and Metoclopramide.
Berger J; Lester P; Rodrigues L
Am J Hosp Palliat Care; 2016 May; 33(4):407-10. PubMed ID: 25646530
[TBL] [Abstract][Full Text] [Related]
35. Randomized clinical trial comparing octreotide and scopolamine butylbromide in symptom control of patients with inoperable bowel obstruction due to advanced ovarian cancer.
Peng X; Wang P; Li S; Zhang G; Hu S
World J Surg Oncol; 2015 Feb; 13():50. PubMed ID: 25889313
[TBL] [Abstract][Full Text] [Related]
36. Octreotide improved the quality of life in a child with malignant bowel obstruction caused by peritoneal dissemination of colon cancer.
Watanabe H; Inoue Y; Uchida K; Okugawa Y; Hiro J; Ojima E; Kobayashi M; Miki C; Kusunoki M
J Pediatr Surg; 2007 Jan; 42(1):259-60. PubMed ID: 17208578
[TBL] [Abstract][Full Text] [Related]
37. Octreotide.
Murphy E; Prommer EE; Mihalyo M; Wilcock A
J Pain Symptom Manage; 2010 Jul; 40(1):142-8. PubMed ID: 21634046
[No Abstract] [Full Text] [Related]
38. Octreotide in relieving gastrointestinal symptoms due to bowel obstruction.
Mercadante S; Spoldi E; Caraceni A; Maddaloni S; Simonetti MT
Palliat Med; 1993; 7(4):295-9. PubMed ID: 7505187
[TBL] [Abstract][Full Text] [Related]
39. Palliative Medical Management of Inoperable Malignant Bowel Obstruction With "Triple Therapy": Dexamethasone, Octreotide, and Metoclopramide.
Wey W; Mian M; Calabrese R; Hansen E; Walter M; Wang C; Miller A; Case AA
Am J Hosp Palliat Care; 2021 Apr; 38(4):340-345. PubMed ID: 33084354
[TBL] [Abstract][Full Text] [Related]
40. Palliative care for intestinal obstruction in recurrent ovarian cancer: a multivariate analysis.
Mangili G; Aletti G; Frigerio L; Franchi M; Panacci N; Viganò R; DE Marzi P; Zanetto F; Ferrari A
Int J Gynecol Cancer; 2005; 15(5):830-5. PubMed ID: 16174232
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
